Osteoarthritis Therapeutics Market (2026 - 2033) Size, Share & Trends Analysis Report By Product (Viscosupplements, Bone Graft Substitutes, Adipose Tissue Therapy), By Application (Knee Osteoarthritis, Hip Osteoarthritis), By Primary User, By Region, And Segment Forecasts

Osteoarthritis Therapeutics Market Summary

According to the Global Burden of Disease (GBD) Study 2020, approximately 595 million people worldwide were living with osteoarthritis, representing 7.6% of the global population. This number continues to rise, primarily due to demographic shifts and lifestyle factors such as aging and obesity. The GBD report, published in November 2024, noted a sharp increase in OA cases, with approximately 466.3 million new cases recorded in 2021 alone. The condition most commonly affects weight-bearing joints, particularly the knee, making it a growing concern for healthcare systems worldwide. The rise in OA prevalence is particularly pronounced among older populations, with data from the Centers for Disease Control and Prevention (CDC) published in February 2024 indicating that arthritis rates increase substantially with age. In adults aged 75 and older, the prevalence of arthritis is as high as 53.9%, underscoring the strong correlation between aging and OA.

The growing geriatric population is a major driver of market growth, with the World Health Organization (WHO) projecting that by 2050, 16% of the global population will be aged 65 or older. As the elderly population expands, particularly in regions such as Japan and Europe where the aging demographic is more pronounced, the demand for age-specific OA treatments is rising. According to the WHO’s July 2023 report, 73% of individuals living with osteoarthritis are aged 55 or older, highlighting the increasing prevalence of OA in older age groups. This demographic shift has prompted the healthcare industry to focus on therapies that address the unique needs of elderly patients, many of whom also have multiple comorbidities. As of October 2024, healthcare systems are focusing more on geriatric care, emphasizing the development of treatments that improve mobility and overall quality of life for elderly OA patients.  Moreover, the growth of the elderly population is catalyzing investments in clinical research to develop innovative therapies, such as biologics and regenerative treatments, aimed at slowing disease progression and enhancing joint function.

Another significant factor driving the osteoarthritis therapeutics market is the rising incidence of sports injuries and accident-related joint damage. As participation in sports and physical activities continues to increase, so does the risk of injuries that lead to joint damage and accelerate the onset of OA. In addition to the direct impact on treatment modalities, these injuries contribute to a growing awareness of the need for joint health management. The International Labour Organization (ILO), in its 2024 report, estimated that 395 million workers worldwide sustain non-fatal work injuries annually, many of which result in long-term joint damage and subsequent OA. Furthermore, the World Health Organization (WHO) reported in 2024 that injuries account for around 4.4 million deaths annually, with a significant portion of these fatalities linked to road accidents. This growing awareness has led to increased interest in preventative measures, such as nutritional supplements, physical therapy, and the development of novel OA treatments aimed at maintaining joint health and improving recovery outcomes. As a result, the osteoarthritis therapeutics market is experiencing an uptick in the development of therapies designed to address both the prevention and treatment of OA, further contributing to market growth.

Market Concentration & Characteristics

The osteoarthritis (OA) treatment market is evolving with significant innovation, particularly in disease-modifying treatments (DMOADs), biologics, and regenerative therapies. Advancements include stem cell therapies such as StemOne, launched by Alkem Laboratories in September 2022, which aims to repair knee joint cartilage, and the development of tissue-engineered implants. In addition, biologics, such as monoclonal antibodies, are being tested to target disease pathways. AI-driven diagnostics for joint degeneration are also emerging, offering personalized care options. However, much of this innovation is still in the trial phase, and long-term efficacy remains unproven, making it a high-risk, high-reward area for the industry. 

Entering the OA treatment market is challenging due to high development costs, long clinical timelines, and regulatory hurdles. For instance, stem cell therapies such as CARTISTEM are facing regulatory delays, with companies investing over a decade in development. Even after regulatory approval, market access involves establishing distribution networks and navigating reimbursement policies. The rise of generic drugs and biosimilars, like ABP-980 for arthritis, adds further competition, making it difficult for new players to differentiate their products and capture market share without offering innovative solutions or significant improvements.

Regulations play a crucial role in shaping the OA treatment market. The FDA, EMA, and other regulatory bodies require extensive clinical trial data to approve new therapies, especially biologics and regenerative treatments. For example, Pfizer’s tanezumab faced rejection by the FDA in March 2021 due to concerns over its safety profile. Moreover, reimbursement agencies such as NICE in the UK have delayed coverage of some innovative OA treatments due to cost concerns. These regulations ensure safety but also slow the introduction of new therapies, increasing the development costs and limiting accessibility.

Traditional chemotherapy remains a therapeutic option but is increasingly replaced by targeted and immuno-oncology agents due to better response and tolerability. Hematopoietic stem cell transplantation acts as a curative alternative in selected patients, limiting drug demand in eligible cases. Emerging modalities such as allogeneic CAR-T, gene editing, and tumor-specific vaccines may shift future treatment paradigms. Supportive therapies and palliative care can substitute aggressive treatment in late-stage or elderly populations. However, no direct substitute offers equivalent therapeutic value for advanced targeted agents in most leukemia subtypes.

Geographical expansion in the OA treatment market varies by region. Mature markets like North America and Europe, driven by an aging population, face intense competition and require differentiation through innovative therapies. In contrast, emerging markets, particularly in Asia-Pacific, offer growth potential as urbanization and obesity rates rise, contributing to increasing OA prevalence. The WHO projects significant growth in the elderly population in China and India by 2050, further driving demand for OA treatments. However, in these regions, affordability remains a critical challenge, with pharmaceutical companies needing to adapt their products to meet local economic conditions while navigating varying regulatory environments.

Product Insights

Visco supplementation segment dominated the market with the largest revenue share of 48.42% in 2025, led by hyaluronic acid (HA) injections, has become a significant treatment option for knee osteoarthritis (OA). In 2024, HA brands like Synvisc, Durolane, and Monovisc gained popularity as alternatives to NSAIDs and corticosteroids, offering pain relief and improved mobility in mild to moderate OA. Advances in HA formulations, such as cross-linked and high-molecular-weight versions, provide longer-lasting pain relief. In June 2024 Nature Reviews Rheumatology article highlighted the effectiveness of HA in early-stage knee OA, with new combinations like HA and platelet-rich plasma (PRP) enhancing outcomes. As treatment strategies evolve, patient selection based on OA severity is improving the efficacy of Visco supplementation in personalized care plans. 

The Other (Cartilage Resurfacing Products) segment is projected to grow at highest CAGR over the forecast period, which is increasingly important in the osteoarthritis (OA) treatment market, focusing on patients with localized cartilage defects who are not yet candidates for total joint replacement. Products like HemiCAP and BioPoly restore joint surface integrity while preserving native cartilage and bone, offering a less invasive alternative to full arthroplasty with reduced recovery times. Agili-C, an aragonite-based implant, has demonstrated positive clinical results in delaying joint replacement, with a lower risk of progression to full surgery. Innovations such as 3D-printed implants and customized metal-polymer devices are improving precision in resurfacing damaged cartilage. As clinical data supporting these products increases, they are becoming more integrated into treatment plans, especially for younger, active patients, delaying the need for major surgery.

Application Insights

The knee osteoarthritis (OA) segment dominated the market with the largest revenue share of 59.46% in 2025, driven by the high prevalence of the condition and increasing global incidence. Knee OA, characterized by cartilage degradation and reduced joint mobility, is rising due to factors like obesity, aging populations, and sedentary lifestyles. WHO data from March 2024 reports that 2.5 billion adults were overweight in 2022, with 890 million obese. Treatment options range from conservative approaches like physical therapy to invasive procedures such as knee replacement. The demand for minimally invasive treatments has led to innovations such as hyaluronic acid injections, PRP therapy, and Genicular Artery Embolization (GAE), which offers pain relief with minimal recovery. Advances in wearable devices and digital health platforms also enhance treatment adherence. With rising healthcare expenditure and government initiatives, knee OA remains a key focus area in the osteoarthritis therapeutics market, with continued R&D efforts aimed at improving patient outcomes.

The Ankle & Foot Osteoarthritis segment is projected to grow at the fastest CAGR over the forecast period, driven by the increasing adoption of innovative, less invasive treatments. Procedures such as ankle distraction arthroplasty and stem cell therapy are reshaping treatment approaches. For example, a December 2023 study showed that ankle distraction arthroplasty, using an Ilizarov external fixator, led to significant improvements in pain scores, ankle range of motion, and hindfoot function in young patients with moderate-to-severe ankle OA. This procedure, which applies mechanical force to stimulate cartilage regeneration, is emerging as a joint-preserving alternative to traditional treatments. Similarly, the growing clinical burden of foot osteoarthritis, with a reported 16.7% prevalence in adults aged 50 and older, is driving demand for specialized therapies. Advances in diagnostic capabilities and biologically regenerative solutions are further fueling this growth, making ankle and foot OA a key focus within the broader osteoarthritis therapeutics market.

Primary User Insights

The Orthopedic Surgeons segment dominated the market with the largest revenue share of 37.33% in 2025, driven by the increasing adoption of innovative cartilage restoration technologies such as the Agili-C implant. Engineered from aragonite, this biologic implant supports bone and cartilage integration and is particularly beneficial for patients not yet candidates for total knee replacement. A pivotal four-year study, set to release in May 2025, demonstrated an 87% lower relative risk of conversion to total knee arthroplasty in patients treated with the Agili-C implant compared to standard care procedures. Surgeons favor this minimally invasive, single-step procedure due to its ability to restore joint function and delay major surgeries. With growing demand for knee replacement alternatives, orthopedic clinics are increasingly integrating Agili-C into their treatment protocols. Smith+Nephew’s acquisition of CartiHeal further facilitates the implant's dissemination among orthopedic surgeons, who are actively refining surgical techniques and patient education through real-world data and clinical experience. As biologic solutions gain traction, orthopedic surgeons are expected to play a central role in expanding the use of cartilage resurfacing implants.

The Regenerative Medicine Specialists segment is projected to grow at the fastest CAGR over the forecast period, fueled by the increasing adoption of biologic therapies for osteoarthritis. Specialists in this field are at the forefront of non-surgical treatments, administering platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), adipose-derived stem cells, and exosome-based solutions in outpatient settings. According to a January-April 2025 research roundup by MDBiologix, there is strong clinical support for leukocyte-poor PRP, particularly in knee OA management, with improvements in function and pain, especially when guided by ultrasound. In addition, regenerative medicine specialists are exploring platelet lysate (PL) as an alternative or adjunct to PRP, due to its favorable safety profile and cartilage repair properties. Studies on stromal vascular fraction (SVF) derived from adipose tissue are also gaining traction for their ability to support joint healing and cartilage regeneration. These therapies offer shorter recovery times and fewer adverse effects, making them particularly attractive to younger, active patients, driving the growth of this segment.

Regional Insights

North America osteoarthritis therapeutics market held the largest share of 48.07% of the global market in 2025, driven by the high prevalence of osteoarthritis, particularly among the aging population. The region benefits from advanced healthcare infrastructure and significant investments in research and development, which facilitate the introduction of innovative treatments, including regenerative therapies. The increasing patient awareness about the benefits of early diagnosis and treatment further supports market expansion. In addition, favorable reimbursement policies enhance access to advanced therapies, enabling a wider adoption of effective treatments. The presence of leading pharmaceutical and biotechnology companies in North America continues to drive the development and commercialization of new therapies, further contributing to the market's growth.

U.S. Osteoarthritis Therapeutics Market Trends

In the U.S., the osteoarthritis therapeutics market is significantly influenced by the high prevalence of the condition, combined with the country’s advanced healthcare infrastructure and focus on innovative treatment options. Investment in research and development by pharmaceutical and biotechnology companies has led to the introduction of new therapies, particularly in regenerative medicine. The demand for early diagnosis and treatment, along with supportive reimbursement policies, continues to propel the market. Notably, in May 2023, the U.S. FDA granted Breakthrough Therapy Designation to Grünenthal’s investigational nonopioid medication Resiniferatoxin (RTX) for knee osteoarthritis pain, expected to launch by 2026. The rise of generic drug offerings, such as Lupin Pharmaceuticals’ authorized generic version of PENNSAID for knee OA pain, also reflects the growing market demand for cost-effective treatments.

Europe Osteoarthritis Therapeutics Market Trends

The osteoarthritis therapeutics market in Europe is expanding, driven by a combination of advanced healthcare systems, significant government spending on healthcare, and robust research and development activities. The rapidly aging population, which is more susceptible to osteoarthritis, is a primary factor driving the demand for effective treatments. European countries benefit from well-established insurance systems that improve access to advanced therapies, supporting market growth. Ongoing awareness campaigns and patient education initiatives about osteoarthritis management are also contributing to earlier diagnoses and increased treatment uptake. Furthermore, the presence of leading biopharmaceutical companies and research institutions across Europe continues to drive innovation, facilitating the development and commercialization of new treatments, particularly in biologics and regenerative medicine.

The UK osteoarthritis therapeutics market is driven by a well-established healthcare system, with widespread access to advanced treatments through the National Health Service (NHS). Significant investment in research and development, particularly in the field of regenerative medicine, further supports market growth. Ongoing campaigns to raise awareness about osteoarthritis and its management, combined with a high prevalence of the condition in the aging population, continue to boost demand for effective treatments. Research initiatives, such as studies led by the University of Manchester and Link Biologics in June 2023, highlight the development of new treatments offering disease-modifying and pain-relieving benefits. The increasing focus on early diagnosis and prevention, as emphasized by organizations such as Arthritis Research UK, is also driving efforts to improve patient outcomes and reduce the long-term impact of the disease.

Germany's osteoarthritis therapeutics market is supported by a strong healthcare infrastructure and significant investment in medical research and technology. The country’s advanced medical technology sector has facilitated the adoption of innovative therapies, further contributing to market expansion. A rapidly aging population, along with a high prevalence of osteoarthritis, increases the demand for treatment options. Germany's robust insurance system ensures better access to these advanced therapies. Clinical trials, such as the European research collaboration on engineered cartilage for patellofemoral osteoarthritis, are helping to shape the future of treatment in the country. Germany's significant investment in these clinical trials, including a EUR 11 million investment from the EU, continues to drive innovation, creating new treatment avenues for osteoarthritis.

In France, the osteoarthritis therapeutics market benefits from a comprehensive healthcare system supported by significant government expenditure. The presence of leading biopharmaceutical companies and research institutions drives the development of new treatment options, especially in regenerative medicine. Increasing awareness about osteoarthritis, particularly among the aging population, has led to greater demand for effective treatments. Research efforts, such as the 2024 study on the long-term benefits of high-volume PRP injections for knee osteoarthritis, further support the growth of the market. Government initiatives aimed at improving healthcare access, along with ongoing studies in innovative therapies, are also contributing to the market’s expansion. France’s healthcare system, based on a social insurance model, plays a key role in ensuring that new treatments are accessible to the broader population.

Asia Pacific Osteoarthritis Therapeutics Market Trends

The osteoarthritis therapeutics market in the Asia Pacific region is expected to experience rapid growth, driven by the rising prevalence of osteoarthritis and a growing middle-class population with increasing healthcare expenditure. Investments in healthcare infrastructure and research and development are facilitating the introduction of advanced treatment options. Government initiatives to improve healthcare access and raise awareness about osteoarthritis management are also supporting market expansion. The region’s aging population, particularly in countries such as Japan, China, and India, is creating significant demand for effective osteoarthritis therapeutics. In addition, the growing adoption of regenerative medicine and non-invasive treatments is contributing to the overall market growth.

In Japan, the osteoarthritis therapeutics market is primarily driven by the rapidly aging population, which has a high prevalence of the condition. The country’s advanced healthcare infrastructure and significant investment in regenerative medicine support the market’s growth. The Japanese government’s focus on improving healthcare services and patient education on osteoarthritis management is also playing a critical role. Notable developments, such as Japan Tissue Engineering’s (J-TEC) expansion of its regenerative medical product, JACC, for knee osteoarthritis, highlight Japan’s shift toward advanced, personalized treatment approaches. The approval of JACC for knee osteoarthritis by the Ministry of Health, Labor, and Welfare in May 2025 marks a significant milestone in the adoption of regenerative therapies in Japan.

The osteoarthritis therapeutics market in China is expanding due to the rising prevalence of the condition, a growing middle-class population, and increasing healthcare expenditure. Government initiatives aimed at improving healthcare infrastructure and access to advanced treatments are contributing significantly to market growth. The country’s rapid economic development has led to higher spending on healthcare, enabling greater access to both traditional and innovative treatment options. Ongoing research and development in regenerative medicine, coupled with the increasing awareness of osteoarthritis and its management, are further driving the demand for effective therapies. Key initiatives, such as the launch of Synovian, a single-injection treatment for knee osteoarthritis, are positioning China as a key player in the market, particularly with the inclusion of Synovian in the National Reimbursement Drug List, which enhances its market access.

Latin America Osteoarthritis Therapeutics Market Trends

The osteoarthritis therapeutics market in Latin America is experiencing growth, driven by an expanding geriatric population and an increasing prevalence of osteoarthritis, particularly among older adults. According to the Economic Commission for Latin America and the Caribbean (ECLAC), nearly 90 million people aged 60 and older were recorded in June 2024, representing over 13% of the region’s population. This demographic shift is significantly raising the demand for osteoarthritis therapies, particularly as older adults seek improved mobility and pain relief. Government initiatives to improve healthcare access, along with increasing healthcare expenditure, are supporting market expansion. As the elderly population is expected to double by 2050, the osteoarthritis burden in the region is projected to intensify, increasing the demand for both conventional and regenerative therapies. Countries such as Brazil, Mexico, and Argentina are witnessing greater investments in orthobiologics, physical therapy infrastructure, and research into innovative treatment options. Furthermore, improved awareness and early intervention are contributing to better patient outcomes, making the region a key area for growth in the osteoarthritis therapeutics market.

Middle East & Africa Osteoarthritis Therapeutics Market Trends

The osteoarthritis therapeutics market in the Middle East & Africa (MEA) is expanding, driven by an aging population and the growing prevalence of musculoskeletal disorders. Age-related joint degeneration, coupled with rising obesity rates, has led to an increased incidence of osteoarthritis in countries such as the UAE, Saudi Arabia, and South Africa. Urban lifestyles, limited physical activity, and a lack of early intervention exacerbate joint health challenges across the region. Healthcare systems are improving their capacity to manage chronic joint pain by enhancing diagnostic capabilities and treatment options. National policies are increasingly focusing on providing affordable, effective therapies for managing degenerative conditions, contributing to the rising demand for pharmacologic and non-invasive treatments. The region's growing healthcare infrastructure and the shift toward value-based care models support the market's growth.

The osteoarthritis therapeutics market in Saudi Arabia is growing, driven by government investment in healthcare infrastructure, an aging population, and the rising prevalence of osteoarthritis. Significant advancements in regenerative therapy research and development, along with increasing patient awareness and educational initiatives, are supporting market growth. Strategic partnerships, such as Levolta Pharmaceuticals’ collaboration with Tabuk Pharmaceuticals to introduce the investigational drug VOLT01, aim to fill gaps in current treatment options. This drug has shown promise in Phase II/III trials for pain relief and disease modification, with its introduction expected to significantly impact the Saudi market. These developments align with the country's Vision 2030 healthcare goals, improving patient outcomes and expanding access to innovative osteoarthritis therapies.

Kuwait’s osteoarthritis therapeutics market is expanding, driven by the growing prevalence of the condition and a rapidly aging population. The country’s well-developed healthcare infrastructure and significant government investment in medical technologies support the adoption of advanced treatment options. According to the United Nations Population Fund (UNFPA), Kuwait’s elderly population, aged 60 and above, is expected to rise from 7.6% of the population in 2020 to 39.6% by 2050, significantly increasing the demand for osteoarthritis therapeutics. This demographic shift is placing pressure on the healthcare system to provide specialized geriatric care and musculoskeletal services. As the number of high-risk individuals grows, demand for osteoarthritis therapies, including joint injections and pain management, is expected to surge. This trend presents opportunities for healthcare providers and pharmaceutical companies to introduce advanced treatment options, further driving market growth.

Key Osteoarthritis Therapeutics Company Insights

Stryker Corporation participates in the osteoarthritis therapeutics market with a strong focus on orthopedic solutions, including joint replacement systems and minimally invasive therapies. Zimmer Biomet Holdings, Inc. leads with advanced joint replacement technologies and biologics for OA-related joint degeneration. Medtronic expands its presence with minimally invasive procedures and diagnostic tools aimed at improving patient outcomes. Bioventus focuses on regenerative medicine, particularly with its DUROLANE hyaluronic acid treatments and orthobiologics. Anika Therapeutics, Inc. drives innovation with hyaluronic acid-based therapies and regenerative biologics for joint pain management and cartilage repair.

Recent Developments

• In November 2024, Zimmer Biomet secured FDA PMA Supplement approval for its Oxford Cementless Partial Knee, supported by data from an IDE study and non-clinical evaluations. The device demonstrated superior fixation, increased implant longevity, and greater efficiency in the operating room, becoming the sole cementless partial knee implant approved by the FDA in the U.S.

• In August 2024, Vericel Corporation announced that the U.S. FDA approved MACI for treating symptomatic, full-thickness knee cartilage defects in pediatric patients aged 12 to 17. The approval was based on extrapolated adult data and adolescent safety findings, making MACI the first FDA-approved cartilage repair product for pediatric use in the U.S.

• In August 2024, Stryker launched InSpace, a first-of-its-kind biodegradable subacromial balloon implant in India for treating massive irreparable rotator cuff tears.

• In July 2024, Anika Therapeutics, Inc. released its Integrity Implant System, a regenerative scaffold designed for rotator cuff and tendon repairs. The system, which received 510(k) approval from the FDA in August 2023, utilizes hyaluronic acid to support tissue regeneration and healing, aimed at improving patient outcomes in orthopedic surgeries.

Osteoarthritis Therapeutics Market Report Scope

Global Osteoarthritis Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global osteoarthritis therapeutics market report based on product, application, primary user, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Viscosupplements

  • Platelet-Rich Plasma (PRP) Therapy

  • Bone Graft Substitutes

  • BMAC (Bone Marrow Aspirate Concentrate) Therapy

  • Adipose Tissue Therapy

  • Autologous Chondrocyte Implantation (ACI), Including MACI

  • Stem Cell (other)

  • Other (Cartilage Resurfacing Products)

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Knee Osteoarthritis

  • Hip Osteoarthritis

  • Shoulder Osteoarthritis

  • Spine Osteoarthritis

  • Ankle & Foot Osteoarthritis

  • Other

• Primary UserOutlook (Revenue, USD Million, 2021 - 2033)

  • Orthopedic Surgeons

  • Rheumatologists

  • Sports Medicine Specialists

  • Regenerative Medicine Specialists

  • Other

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait